Your browser doesn't support javascript.
loading
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants.
Kuramochi, Taichi; Gan, Siok Wan; Ho, Adrian W S; Wang, Bei; Kageji, Nagisa; Nambu, Takeru; Iida, Sayaka; Okuda-Miura, Momoko; Chia, Wei Shan; Yeo, Chiew Ying; Chen, Dan; Lee, Wen-Hsin; Ngoh, Eve Zi Xian; Mohd Salleh, Siti Nazihah; Wang, Cheng-I; Igawa, Tomoyuki; Shimada, Hideaki.
Afiliación
  • Kuramochi T; Discovery Biologics Department, Research Division, Chugai Pharmaceutical Co., Ltd., Kamakura, Kanagawa, Japan.
  • Gan SW; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Ho AWS; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Wang B; Pharmacology Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Nambu T; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Iida S; Pharmacokinetics Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Okuda-Miura M; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Chia WS; Pharmacokinetics Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Yeo CY; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Chen D; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Lee WH; Protein Production Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Ngoh EZX; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Mohd Salleh SN; Lead Optimization Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Wang CI; Protein Analysis Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Igawa T; Lead Optimization Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
  • Shimada H; Pharmacology Unit, Research Division, Chugai Pharmabody Research Pte. Ltd, Singapore.
MAbs ; 14(1): 2040350, 2022.
Article en En | MEDLINE | ID: mdl-35293276
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / COVID-19 Límite: Humans Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Japón
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Glicoproteína de la Espiga del Coronavirus / COVID-19 Límite: Humans Idioma: En Revista: MAbs Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Japón